Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF Mutant Metastatic Colorectal Cancer Patients

PURPOSE: BRAF mutant metastatic colorectal cancer (mCRC) forms an aggressive subset of colorectal cancer with minimal response to selective RAF inhibitors. Preclinical data show that reactivation of epidermal growth factor receptor (EGFR) signaling occurs in colorectal tumor cells treated with RAF i...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Autores principales: Yaeger, Rona, Cercek, Andrea, O'Reilly, Eileen M., Reidy, Diane L., Kemeny, Nancy, Wolinsky, Tamar, Capanu, Marinela, Gollub, Marc J., Rosen, Neal, Berger, Michael F., Lacouture, Mario E., Vakiani, Efsevia, Saltz, Leonard
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546416/
https://ncbi.nlm.nih.gov/pubmed/25589621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2779
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares